Clinical Trials Logo

Disease clinical trials

View clinical trials related to Disease.

Filter by:

NCT ID: NCT00036309 Completed - Depressive Disorder Clinical Trials

Duloxetine Versus Placebo in the Prevention of Relapse of Major Depressive Disorder

Start date: May 2002
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if duloxetine is effective when compared to placebo in preventing recurrence of major depressive disorder in patients who have responded to open-label duloxetine treatment.

NCT ID: NCT00035802 Completed - Bipolar Disorder Clinical Trials

A Study to Evaluate the Safety and Effectiveness of Topiramate Compared to Placebo in the Treatment of Patients With Bipolar I Disorder

Start date: January 2002
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of topiramate in adolescents with manic or mixed episodes of Bipolar I Disorder.

NCT ID: NCT00035295 Completed - Clinical trials for Major Depressive Disorder

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061)

Start date: November 8, 2001
Phase: Phase 3
Study type: Interventional

A clinical study to determine the efficacy and safety of an Treatment of MK0869 in the treatment of depression.

NCT ID: NCT00035048 Completed - Clinical trials for Major Depressive Disorder

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED)

Start date: November 21, 2001
Phase: Phase 3
Study type: Interventional

A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression.

NCT ID: NCT00035009 Completed - Clinical trials for Major Depressive Disorder

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059)

Start date: September 20, 2001
Phase: Phase 3
Study type: Interventional

A clinical study to determine the efficacy and safety of MK0869 in the treatment of depression

NCT ID: NCT00034983 Completed - Clinical trials for Major Depressive Disorder

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-066)(COMPLETED)

Start date: October 29, 2001
Phase: Phase 3
Study type: Interventional

A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression

NCT ID: NCT00034944 Completed - Clinical trials for Major Depressive Disorder

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)

Start date: January 24, 2002
Phase: Phase 3
Study type: Interventional

A clinical study to determine the efficacy and safety of MK0869 in the treatment of depression.

NCT ID: NCT00034892 Completed - Schizophrenia Clinical Trials

CAFE Comparison of Atypicals in First Episode of Psychosis

Start date: March 2002
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the effectiveness, tolerability, and efficacy of the currently available atypical antipsychotic drugs olanzapine (2.5-20 mg/day), quetiapine (100-800 mg/day) and risperidone (0.5-4 mg/day) in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder who are experiencing their first psychotic episode.

NCT ID: NCT00033995 Completed - Tourette Syndrome Clinical Trials

Study of Tics in Patients With Tourette's Syndrome and Chronic Motor Tic Disorder

Start date: April 17, 2002
Phase: N/A
Study type: Observational

This study will investigate which areas of the brain are primarily involved in and responsible for tics in patients with Tourette's syndrome and chronic motor disorder. Tourette's syndrome is a neuropsychiatric disorder characterized by motor and vocal tics and is associated with behavioral and emotional disturbances, including symptoms of attention deficit hyperactivity disorder and obsessive-compulsive disorder. Chronic motor disorder has the same characteristics as Tourette's syndrome, except that patients do not have vocal tics. Healthy normal volunteers and patients with Tourette's syndrome or chronic motor tic disorder between 18 and 65 years of age may be eligible for this study. Candidates will be screened with a medical history and physical and neurological examinations. Participants will undergo positron emission tomography (PET) scanning to study tics under three conditions- spontaneous tics, suppression of tics, and sleep-to determine which areas of the brain are responsible for generation of tics. For this procedure, the subject is injected with H215O, a radioactive substance similar to water. A special camera detects the radiation emitted by the H215O, allowing measurement of brain blood flow. Subjects will receive up to 20 injections of H215O during the scanning. Participants will be asked not to sleep the entire night before the test. Before the scan, both patients and volunteers will have EEG electrodes placed on their heads to record the electrical activity of their brains. Patients will also have EMG electrodes placed in areas of the body where tics occur. A small catheter (plastic tube) will be placed in an arm vein for injecting the radioactive tracers, and a mask will be placed on the face to help keep the head still during scanning. The mask has large openings for eyes, nose and mouth, so that it does not interfere with talking or breathing. The entire test takes about 4 hours. During this time, the subject will sleep for 1.5 hours either at the beginning or end of the scan. For the other 2.5 hours, scans will be done every 10 minutes for 1 minute under the different conditions of tic suppression or release of tics. On a separate day, participants will also undergo magnetic resonance imaging (MRI), a diagnostic test that uses a magnetic field and radio waves to produce images of the brain. For this procedure, the subject lies still on a stretcher that is moved into the scanner (a narrow cylinder containing the magnet). ...

NCT ID: NCT00033111 Completed - Clinical trials for Substance-Related Disorders

A Study of Cabergoline for the Treatment of Cocaine Dependence - 1

Start date: June 2001
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess cabergoline for the Treatment of Cocaine Dependence